Abstract
Get full access to this article
View all access options for this article.
References
1.
Altorki N.
,
Heymach J.
,
Guarino M.
Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): a proof-of-concept study [abstract 2250] . Ann Oncol. 2008 ; 19 (8 ): viii . http://proquest.umi.com/pqdweb?index=9&did=1570727961&SrchMode=3&sid=1&Fmt=6&VInst=PROD&VType=PQD&RQT=309&VName=PQD&TS=1258560357&clientId=29381&aid=1. Accessed November 12, 2009.
2.
Dejonge M.
,
Savage S.
,
Verweij J.
A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently [abstract 3088] . Proc Am Soc Clin Oncol. 2006 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=34591. Accessed November 12, 2009.
3.
Friedlander M.
,
Hancock K.C.
,
Benigno B.
Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: results of a phase II study [abstract 6630] . Ann Oncol. 2008 ; 19 (8 ): viii1 –viii4 . http://proquest.umi.com/pqdweb?index=35&did=1570728171&SrchMode=3&sid=1&Fmt=6&VInst=PROD&VType=PQD&RQT=309&VName=PQD&TS=1258560923&clientId=29381&aid=1. Accessed November 12, 2009.
4.
Hawkins R.E.
,
Hong S.J.
,
Ulys A.
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC) [abstract 5110] . Proc Am Soc Clin Oncol. 2009 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34777. Accessed November 12, 2009.
5.
Hurwitz H.I.
,
Dowlati A.
,
Saini S.
Phase I trial of pazopanib in patients with advanced cancer . Clin Cancer Res. 2009 ; 15 (12 ): 4220 –4227 .
6.
Hutson T.E.
,
Davis I.D.
,
Machiels J.P.
Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT) [abstract 5031] . Proc Am Soc Clin Oncol. 2007 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=33945. Accessed November 12, 2009.
7.
Hutson T.E.
,
Bukowski R.M.
A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma . Clin Genitourin Cancer. 2006 ; 4 (4 ): 296 –298 .
8.
Prince H.M.
,
Hönemann D.
,
Spencer A.
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034) . Blood 2009 ; 113 (19 ): 4819 –4820 .
9.
Sleijfer S.
,
Ray-Coquard I.
,
Papai Z.
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-soft tissue and bone sarcoma group (EORTC study 62043) . J Clin Oncol 2009 ; 27 (19 ): 3126 –3132 .
10.
Slamon D.
,
Gomez H.
,
Amit O.
Pazopanib + lapatinib is more active than lapatinib alone: updated results from a randomized study in patients with erbb2 positive advanced or metastatic breast cancer [abstract 139P] . Ann Oncol. 2008 . http://proquest.umi.com/pqdweb?index=7&did=1570728151&SrchMode=3&sid=1&Fmt=6&VInst=PROD&VType=PQD&RQT=309&VName=PQD&TS=1258561446&clientId=29381&aid=1. Accessed November 12, 2009.
11.
Sternberg C.N.
,
Szczylik C.
,
Lee E.
A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine pretreated patients with advanced renal cell carcinoma (RCC) [abstract 5021] . Proc Am Soc Clin Oncol. 2009 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30883. Accessed November 12, 2009.
12.
Suttle B.
,
Jones S.
,
Dowlati A.
Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034) [abstract 14118] . Proc Am Soc Clin Oncol. 2007 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32947. Accessed November 12, 2009.
13.
Suttle A.B.
,
Hurwitz H.
,
Dowlati A.
Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors [abstract 3054] . Proc Am Soc Clin Oncol. 2004 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2239. Accessed November 12, 2009.
14.Votrient™ [product information]. Research Triangle Park, NC : GlaxoSmithKline ; 2009 . http://www.votrient.com/index.html. Accessed November 12, 2009.
15.
Horwitz S.M.
,
Vose J.M.
,
Advani R.
A Phase 1/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies [abstract 1570] . Proc Am Soc Hematol. 2008 . http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/1570?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=pralatrexate&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT. Accessed November 12, 2009.
16.
Horwitz S.M.
,
Duvic M.
,
Kim Y.
Pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multi-center dose-finding trial [abstract 1569] . Proc Am Soc Hematol. 2008 . http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/1569?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=pralatrexate&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT. Accessed November 12, 2009.
17.
Grant S.
,
Krug L.
,
Ng K.
Phase I and Pharmacokinetic studies of 10-propargyl-10-deazaaminopterin (PDX) in patients with advanced solid tumors [abstract 815] . Proc Am Soc Clin Oncol. 1999 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=17&abstractID=15068. Accessed November 12, 2009.
18.
Krug L.M.
,
Ng K.K.
,
Kris M.G.
4Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate . Clin Cancer Res. 2000 ; 6 (9 ):3493 –3498 . [Erratum in: Clin Cancer Res. 2001; 7(4): 1102].
19.
O'Connor O.A.
,
Hamlin P.A.
,
Portlock C.
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma . Br J Haematol. 2007 ; 139 (3 ): 425 –428 .
20.
O'Connor O.A.
,
Horwitz S.
,
Hamlin P.
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies . J Clin Oncol. 2009 ; 27 (26 ): 4357 –4364 .
21.
O'Connor O.
,
Pro B.
,
Pinter-Brown L.
PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) [abstract 8561] . Proc Am Soc Clin Oncol. 2009 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35029. Accessed November 12, 2009.
22.
O'Connor O.A.
,
Hamlin P.A.
,
Gerecitano J.
Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral t-cell lymphomas: results of the MSKCC phase I/II experience [abstract 400] . Proc Am Soc Hematol. 2006 . http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/400?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=pralatrexate&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT. Accessed November 12, 2009.
23.Folotyn™ [product information]. Westminster, CO : Allos Therapeutics, Inc. http://www.folotyn.com/pdf/package-insert.pdf, Accessed November 12, 2009.
24.
Fury M.G.
,
Krug L.M.
,
Azzoli C.G.
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors . Cancer Chemother Pharmacol 2006 ; 57 (5 ): 671 –677 .
25.
Azzoli C.G.
,
Krug L.M.
,
Gomez J.
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors . Clin Cancer Res. 2007 ; 13 (9 ): 2692 –2698 .
26.
Krug L.M.
,
Heelan R.T.
,
Kris M.G.
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma . J Thorac Oncol. 2007 ; 2 (4 ): 317 –320 .
27.
Azzoli C.G.
,
Krug L.
,
Miller V.
Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid supplementation in patients (pts) with advanced nonsmall cell lung cancer (NSCLC) [abstract 13006] . Proc Am Soc Clin Oncol. 2007 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=36302. Accessed November 12, 2009.
28.
Azzoli C.G.
,
Krug L.M.
,
Miller V.A.
Phase II study of 10-propargyl-10-deazaaminopter in (PDX) in previously-treated patients with advanced non-small cell lung cancer (NSCLC) [abstract 1321] . Proc Am Soc Clin Oncol. 2001 . http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10&abstractID=1321. Accessed November 12, 2009.